Docket 23-477
Skrmetti
DecidedJun 18, 2025
6-3decision
Source: CourtListener.
Supreme Court upholds Tennessee's ban on puberty blockers and hormones for transgender minors
What it does
The Court held that Tennessee's law does not classify on the basis of sex or transgender status and therefore is not subject to heightened (intermediate) scrutiny under the Equal Protection Clause. Applying the more lenient rational basis standard, the Court found the law is rationally related to Tennessee's stated interest in protecting minors' health and welfare. The ruling affirms that states may restrict puberty blockers and hormones for minors when used to treat gender dysphoria, without needing to meet the higher constitutional bar required for sex-based classifications.
Who benefits
State legislatures that have enacted or wish to enact laws restricting medical treatments for gender dysphoria in minors, whose authority to do so is now constitutionally confirmed. Tennessee and the more than 20 other states with similar laws gain legal certainty that those laws survive Equal Protection challenge under rational basis review.
Who is affected
Transgender minors in Tennessee (and states with similar laws) who seek puberty blockers or hormone therapy to treat gender dysphoria, and their parents and physicians, who are now legally barred from accessing or providing those treatments. Healthcare providers who prescribe such treatments to minors face civil penalties, professional discipline, and private lawsuits under the law.
Practical impact
Transgender minors in Tennessee and states with similar laws cannot legally receive puberty blockers or hormone therapy to treat gender dysphoria, regardless of their parents' wishes or their physicians' medical judgment. Healthcare providers who prescribe such treatments to minors in those states face civil penalties, loss of professional licenses, and private lawsuits. States that have enacted or are considering similar restrictions now have a clear constitutional green light to enforce those laws without fear of Equal Protection challenge under heightened scrutiny.
Majority — Roberts
Joined by: Thomas, Gorsuch, Kavanaugh, Barrett, Alito
The majority held that Tennessee's law (SB1) does not classify on the basis of sex because it restricts specific medical treatments — puberty blockers and hormones used to treat gender dysphoria — for all minors regardless of their sex, and permits those same drugs for other medical purposes regardless of sex. The Court reasoned that a "medical treatment" must be understood to include both the drug and the specific condition it is treating, so banning the drug-plus-diagnosis combination of "hormones to treat gender dysphoria" is a diagnosis-based restriction, not a sex-based one. The majority also held that SB1 does not classify on the basis of transgender status, drawing an analogy to Geduldig v. Aiello (1974), in which the Court held that excluding pregnancy from disability coverage was not sex discrimination — just as not every law about pregnancy is a sex classification, not every law about gender dysphoria is a transgender-status classification. The Court declined to extend the reasoning of Bostock v. Clayton County (a Title VII employment case) to the Equal Protection context, finding that changing a minor's sex would not change SB1's outcome because the bar to treatment is the diagnosis, not the patient's sex. Finally, applying rational basis review, the Court found the law easily satisfied that standard given Tennessee's legislative findings about the experimental nature of these treatments, risks of irreversible harm, and evidence that minors may lack the maturity to fully appreciate those consequences.
Dissent reasoning
The dissent argued that SB1 plainly classifies on the basis of sex because whether a minor can receive puberty blockers or hormones depends directly on the minor's sex — a male minor can receive medications to look more like a boy, while a female minor cannot receive the same medications for the same purpose, and vice versa. Justice Sotomayor wrote that the statute's own text — prohibiting treatment that enables a minor to "identify with" an identity "inconsistent with" the minor's sex — is a facial sex classification, just as a law prohibiting attendance at religious services "inconsistent with" a child's religion would plainly classify on the basis of religion. The dissent contended that the majority's recharacterization of SB1 as a neutral "medical use" restriction is impossible to reconcile with the statute's text, because the very medical purpose SB1 prohibits is defined by reference to the patient's sex. The dissent also argued that SB1 discriminates on the basis of transgender status, because desiring to identify with a gender inconsistent with one's sex is precisely what it means to be transgender, making the affected class and the transgender class wholly coextensive. In the dissent's view, the majority's refusal to apply intermediate scrutiny — the standard the Court has used for sex-based classifications for 50 years — abandons transgender minors and their families to political majorities without the constitutional protection the Equal Protection Clause was designed to provide.
Constitutional question
Does Tennessee's law prohibiting healthcare providers from administering puberty blockers or hormones to minors for the purpose of treating gender dysphoria or gender incongruence violate the Equal Protection Clause of the Fourteenth Amendment?
Precedent changed
The Court extended the reasoning of Geduldig v. Aiello (1974) — which held that excluding pregnancy from disability coverage is not sex discrimination — to the transgender medical context, applying it for the first time to hold that a law targeting gender dysphoria treatment does not classify on the basis of transgender status. The Court declined to extend Bostock v. Clayton County (2020) beyond the Title VII employment context.